A blood-based proteomic classifier for the molecular characterization of pulmonary nodules

Science Translational Medicine

Volumn 5, Issue 207, 2013, Pages

  Li, Xiao Jun ^a   Hayward, Clive ^a   Fong, Pui Yee ^a   Dominguez, Michel ^a,j   Hunsucker, Stephen W ^a   Lee, Lik Wee ^a   McLean, Matthew ^a,k   Law, Scott ^a   Butler, Heather ^a,l   Schirm, Michael ^b   Gingras, Olivier ^b   Lamontagne, Julie ^b   Allard, Rene ^b   Chelsky, Daniel ^b   Price, Nathan D ^c   Lam, Stephen ^d   Massion, Pierre P ^e,f   Pass, Harvey ^g   Rom, William N ^h   Vachani, Anil ⁱ   Fang, Kenneth C ^a   Hood, Leroy ^c   Kearney, Paul ^a   more..

^a Integrated Diagnostics   (United States)

^b Caprion Proteomics   (Canada)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j HyperOmics Farma   (Canada)

^k DuPont Industrial Biosciences   (United States)

^l Blackbeck Research   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; MYC PROTEIN; PROTEIN FOS; TRANSCRIPTION FACTOR NRF2;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASSAY; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER STAGING; CASE CONTROL STUDY; CLASSIFIER; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MATHEMATICAL ANALYSIS; MULTIPLE REACTION MONITORING MASS SPECTROMETRY; OXIDATIVE STRESS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEOMICS; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TUMOR LOCALIZATION; TUMOR VOLUME; VALIDATION PROCESS;

ALGORITHMS; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SOLITARY PULMONARY NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 84886447263     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007013     Document Type: Article

References (71)

1. D. A. Schauer, O. W. Linton, National Council on Radiation Protection and Measurements report shows substantial medical exposure increase. Radiology 253, 293 -296 (2009).
2. S. H. Stern, R. V. Kaczmarek, D. C. Spelic, O. H. Suleiman, Nationwide Evaluation of X-Ray Trends (NEXT) 2000-01 Survey of Patient Radiation Exposure from Computed Tomographic (CT) Examinations in the United States (U.S. Food and Drug Administration, Rockville, MD, 2001).
3. R. S. Wiener, L. M. Schwartz, S. Woloshin, H. G. Welch, Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: An analysis of discharge records. Ann. Intern. Med. 155, 137-144 (2011).
4. H. MacMahon, J. H. Austin, G. Gamsu, C. J. Herold, J. R. Jett, D. P. Naidich, E. F. Patz Jr., S. J. Swensen, S. Fleischner, Guidelines for management of small pulmonary nodules detected on CT scans: A statement from the Fleischner Society. Radiology 237, 395-400 (2005).
5. S. M. Hanash, C. S. Baik, O. Kallioniemi, Emerging molecular biomarkers -Blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol. 8, 142-150 (2011).
6. Y. E. Miller, Minimizing unintended consequences of detecting lung nodules by computed tomography. Am. J. Respir. Crit. Care Med. 178, 891-892 (2008).
7. C. M. Kelly, S. Krishnamurthy, G. Bianchini, J. K. Litton, A. M. Gonzalez-Angulo, G. N. Hortobagyi, L. Pusztai, Utility of Oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116, 5161-5167 (2010).
8. C. Micheel, S. J. Nass, G. S. Omenn, Evolution of Translational Omics: Lessons Learned and the Path Forward (National Academies Press, Washington, DC, 2012).
9. C. V. Pecot, M. Li, X. J. Zhang, R. Rajanbabu, C. Calitri, A. Bungum, J. R. Jett, J. B. Putnam, C. Callaway-Lane, S. Deppen, E. L. Grogan, D. P. Carbone, J. A. Worrell, K. G. Moons, Y. Shyr, P. P. Massion, Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol. Biomarkers Prev. 21, 786-792 (2012).
10. R. M. Ostroff, W. L. Bigbee, W. Franklin, L. Gold, M. Mehan, Y. E. Miller, H. I. Pass, W. N. Rom, J. M. Siegfried, A. Stewart, J. J. Walker, J. L. Weissfeld, S. Williams, D. Zichi, E. N. Brody, Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5, e15003 (2010).
11. W. L. Bigbee, V. Gopalakrishnan, J. L. Weissfeld, D. O. Wilson, S. Dacic, A. E. Lokshin, J. M. Siegfried, A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J. Thorac. Oncol. 7, 698-708 (2012).
12. W. N. Rom, J. D. Goldberg, D. Addrizzo-Harris, H. N. Watson, M. Khilkin, A. K. Greenberg, D. P. Naidich, B. Crawford, E. Eylers, D. Liu, E. M. Tan, Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer 10, 234 (2010).
13. S. Lam, P. Boyle, G. F. Healey, P. Maddison, L. Peek, A. Murray, C. J. Chapman, J. Allen, W. C. Wood, H. F. Sewell, J. F. Robertson, EarlyCDT-Lung: An immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev. Res. 4, 1126-1134 (2011).
14. C. J. Chapman, G. F. Healey, A. Murray, P. Boyle, C. Robertson, L. J. Peek, J. Allen, A. J. Thorpe, G. Hamilton-Fairley, C. B. Parsy-Kowalska, I. K. MacDonald, W. Jewell, P. Maddison, J. F. Robertson, EarlyCDT® -Lung test: Improved clinical utility through additional autoantibody assays. Tumour Biol. 33, 1319-1326 (2012).
15. P. B. Yildiz, Y. Shyr, J. S. Rahman, N. R. Wardwell, L. J. Zimmerman, B. Shakhtour, W. H. Gray, S. Chen, M. Li, H. Roder, D. C. Liebler, W. L. Bigbee, J. M. Siegfried, J. L. Weissfeld, A. L. Gonzalez, M. Ninan, D. H. Johnson, D. P. Carbone, R. M. Caprioli, P. P. Massion, Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J. Thorac. Oncol. 2, 893-901 (2007).
16. T. A. Addona, S. E. Abbatiello, B. Schilling, S. J. Skates, D. R. Mani, D. M. Bunk, C. H. Spiegelman, L. J. Zimmerman, A. J. Ham, H. Keshishian, S. C. Hall, S. Allen, R. K. Blackman, C. H. Borchers, C. Buck, H. L. Cardasis, M. P. Cusack, N. G. Dodder, B. W. Gibson, J. M. Held, T. Hiltke, A. Jackson, E. B. Johansen, C. R. Kinsinger, J. Li, M. Mesri, T. A. Neubert, R. K. Niles, T. C. Pulsipher, D. Ransohoff, H. Rodriguez, P. A. Rudnick, D. Smith, D. L. Tabb, T. J. Tegeler, A. M. Variyath, L. J. Vega-Montoto, A. Wahlander, S. Waldemarson, M. Wang, J. R. Whiteaker, L. Zhao, N. L. Anderson, S. J. Fisher, D. C. Liebler, A. G. Paulovich, F. E. Regnier, P. Tempst, S. A. Carr, Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 27, 633-641 (2009).
17. V. Lange, P. Picotti, B. Domon, R. Aebersold, Selected reaction monitoring for quantitative proteomics: A tutorial. Mol. Syst. Biol. 4, 222 (2008).
18. I. Cima, R. Schiess, P. Wild, M. Kaelin, P. Schüffler, V. Lange, P. Picotti, R. Ossola, A. Templeton, O. Schubert, T. Fuchs, T. Leippold, S. Wyler, J. Zehetner, W. Jochum, J. Buhmann, T. Cerny, H. Moch, S. Gillessen, R. Aebersold, W. Krek, Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 108, 3342-3347 (2011).
19. S. Qin, Y. Zhou, A. S. Lok, A. Tsodikov, X. Yan, L. Gray, M. Yuan, R. L. Moritz, D. Galas, G. S. Omenn, L. Hood, SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics 12, 1244-1252 (2012).
20. X. Zeng, B. L. Hood, M. Sun, T. P. Conrads, R. S. Day, J. L. Weissfeld, J. M. Siegfried, W. L. Bigbee, Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J. Proteome Res. 9, 6440-6449 (2010).
21. T. A. Addona, X. Shi, H. Keshishian, D. R. Mani, M. Burgess, M. A. Gillette, K. R. Clauser, D. Shen, G. D. Lewis, L. A. Farrell, M. A. Fifer, M. S. Sabatine, R. E. Gerszten, S. A. Carr, A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat. Biotechnol. 29, 635-643 (2011).
22. J. R. Whiteaker, C. Lin, J. Kennedy, L. Hou, M. Trute, I. Sokal, P. Yan, R. M. Schoenherr, L. Zhao, U. J. Voytovich, K. S. Kelly-Spratt, A. Krasnoselsky, P. R. Gafken, J. M. Hogan, L. A. Jones, P. Wang, L. Amon, L. A. Chodosh, P. S. Nelson, M. W. McIntosh, C. J. Kemp, A. G. Paulovich, A targeted proteomics - based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 29, 625- 634 (2011).
23. L. E. Hood, G. S. Omenn, R. L. Moritz, R. Aebersold, K. R. Yamamoto, M. Amos, J. Hunter-Cevera, L. Locascio;Workshop Participants, New and improved proteomics technologies for understanding complex biological systems: Addressing a grand challenge in the life sciences. Proteomics 12, 2773-2783 (2012).
24. S. Brunet, P. Thibault, E. Gagnon, P. Kearney, J. J. Bergeron, M. Desjardins, Organelle proteomics: Looking at less to see more. Trends Cell Biol. 13, 629-638 (2003).
25. J. R. Yates III, A. Gilchrist, K. E. Howell, J. J. Bergeron, Proteomics of organelles and large cellular structures. Nat. Rev. Mol. Cell Biol. 6, 702-714 (2005).
26. R. Hüttenhain, M. Soste, N. Selevsek, H. Röst, A. Sethi, C. Carapito, T. Farrah, E. W. Deutsch, U. Kusebauch, R. L. Moritz, E. Niméus-Malmström, O. Rinner, R. Aebersold, Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci. Transl. Med. 4, 142ra94 (2012).
27. M. S. Pepe, The Statistical Evaluation of Medical Tests for Classification and Prediction (Oxford Univ. Press, New York, 2003).
28. National Lung Screening Trial Research; T. R. Church, W. C. Black, D. R. Aberle, C. D. Berg, K. L. Clingan, F. Duan, R. M. Fagerstrom, I. F. Gareen, D. S. Gierada, G. C. Jones, I. Mahon, P. M. Marcus, J. D. Sicks, A. Jain, S. Baum, Results of initial low-dose computed tomographic screening for lung cancer. N. Engl. J. Med. 368, 1980-1991 (2013).
29. S. J. Swensen, M. D. Silverstein, D. M. Ilstrup, C. D. Schleck, E. S. Edell, The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch. Intern. Med. 157, 849 -855 (1997).
30. M. K. Gould, L. Ananth, P. G. Barnett; Veterans Affairs SNAP Cooperative Study Group, A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest 131, 383-388 (2007).
31. H. B. Mann, D. R. Whitney, On a test of whether one of two random variables is stochastically larger than the other. Ann. Math. Stat. 18, 50-60 (1947).
32. L. A. Beer, H. Wang, H. Y. Tang, Z. Cao, T. Chang-Wong, J. L. Tanyi, R. Zhang, Q. Liu, D. W. Speicher, Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera. PLoS One 8, e60129 (2013).
33. P. Picotti, O. Rinner, R. Stallmach, F. Dautel, T. Farrah, B. Domon, H. Wenschuh, R. Aebersold, High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat. Methods 7, 43-46 (2010).
34. T. Hastie, R. Tibshirani, J. Friedman, The Elements of Statistical Learning: Data Mining, Inference, and Prediction (Springer, New York, 2009).
35. D. W. Hosmer, S. Lemeshow, R. X. Sturdivant, Applied Logistic Regression (John Wiley & Sons, Hoboken, ed. 3, 2013).
36. Q. S. Xu, Y. Z. Liang, Monte Carlo cross validation. Chemometr. Intell. Lab. Syst. 56, 1-11 (2001).
37. D. K. McClish, Analyzing a portion of the ROC curve. Med. Decis. Making 9, 190 -195 (1989).
38. H. Meng, G. Chen, X. Zhang, Z. Wang, D. G. Thomas, T. J. Giordano, D. G. Beer, M. M. Wang, Stromal LRP1 in lung adenocarcinoma predicts clinical outcome. Clin. Cancer Res. 17, 2426-2433 (2011).
39. L. Zhao, W. Ji, L. Zhang, G. Ou, Q. Feng, Z. Zhou, M. Lei, W. Yang, L. Wang, Changes of circulating transforming growth factor-b1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer. J. Thorac. Oncol. 5, 521-525 (2010).
40. T. Iizasa, H. Chang, M. Suzuki, M. Otsuji, S. Yokoi, M. Chiyo, S. Motohashi, K. Yasufuku, Y. Sekine, A. Iyoda, K. Shibuya, K. Hiroshima, T. Fujisawa, Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin. Cancer Res. 10, 5361-5366 (2004).
41. T. Okano, T. Kondo, T. Kakisaka, K. Fujii,M. Yamada, H. Kato, T. Nishimura, A. Gemma, S. Kudoh, S. Hirohashi, Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 6, 3938-3948 (2006).
42. C. Papadaki,D. Mavroudis, M. Trypaki, A. Koutsopoulos, E. Stathopoulos, D. Hatzidaki, E. Tsakalaki, V. Georgoulias, J. Souglakos, Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. Clin. Cancer Res. 15, 3827-3833 (2009).
43. C. C. Lin, L. C. Chen, V. S. Tseng, J. J. Yan, W. W. Lai, W. P. Su, C. H. Lin, C. Y. Huang, W. C. Su, Malignant pleural effusion cells show aberrant glucose metabolism gene expression. Eur. Respir. J. 37, 1453-1465 (2011).
44. P. Urban, M. Bilecova-Rabajdova, M. Marekova, J. Vesela, Progression of apoptic signaling from mesenteric ischemia-reperfusion injury to lungs: Correlation in the level of ER chaperones expression. Mol. Cell. Biochem. 362, 133-140 (2012).
45. X. Li, T. Asmitananda, L. Gao, D. Gai, Z. Song, Y. Zhang, H. Ren, T. Yang, T. Chen, M. Chen, Biomarkers in the lung cancer diagnosis: A clinical perspective. Neoplasma 59, 500-507 (2012).
46. A.Marchetti, N. Tinari, F. Buttitta, A. Chella, C. A. Angeletti, R. Sacco, F. Mucilli, A. Ullrich, S. Iacobelli, Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res. 62, 2535-2539 (2002).
47. S. Li, R. Wang, M. Zhang, L. Wang, S. Cheng, Proteomic analysis of non-small cell lung cancer tissue interstitial fluids. World J. Surg. Oncol. 11, 173 (2013).
48. J. M. Jones, N. C. McGonigle, M. McAnespie, G. W. Cran, A. N. Graham, Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 53, 97-101 (2006).
49. B. Efron, R. Tibshirani, Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statist. Sci. 1, 54-75 (1986).
50. D. N. Perkins, D. J. Pappin, D. M. Creasy, J. S. Cottrell, Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551-3567 (1999).
51. D. Radulovic, S. Jelveh, S. Ryu, T. G. Hamilton, E. Foss, Y. Mao, A. Emili, Informatics platform for global proteomic profiling and biomarker discovery using liquid chromatography-tandem mass spectrometry. Mol. Cell. Proteomics 3, 984-997 (2004).
52. X. J. Li, E. C. Yi, C. J. Kemp, H. Zhang, R. Aebersold, A software suite for the generation and comparison of peptide arrays from sets of data collected by liquid chromatography-mass spectrometry. Mol. Cell. Proteomics 4, 1328-1340 (2005).
53. M. Y. Brusniak, B. Bodenmiller, D. Campbell, K. Cooke, J. Eddes, A. Garbutt, H. Lau, S. Letarte, L. N. Mueller, V. Sharma, O. Vitek, N. Zhang, R. Aebersold, J. D. Watts, Corra: Computational framework and tools for LC-MS discovery and targeted mass spectrometry-based proteomics. BMC Bioinformatics 9, 542 (2008).
54. G. S. Omenn, D. J. States, M. Adamski, T. W. Blackwell, R. Menon, H. Hermjakob, R. Apweiler, B. B. Haab, R. J. Simpson, J. S. Eddes, E. A. Kapp, R. L. Moritz, D. W. Chan, A. J. Rai, A. Admon, R. Aebersold, J. Eng, W. S. Hancock, S. A. Hefta, H. Meyer, Y. K. Paik, J. S. Yoo, P. Ping, J. Pounds, J. Adkins, X. Qian, R. Wang, V. Wasinger, C. Y. Wu, X. Zhao, R. Zeng, A. Archakov, A. Tsugita, I. Beer, A. Pandey, M. Pisano, P. Andrews, H. Tammen, D. W. Speicher, S. M. Hanash, Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5, 3226-3245 (2005).
55. D. J. States, G. S. Omenn, T. W. Blackwell, D. Fermin, J. Eng, D. W. Speicher, S. M. Hanash, Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat. Biotechnol. 24, 333-338 (2006).
56. E. W. Deutsch, J. K. Eng, H. Zhang, N. L. King, A. I. Nesvizhskii, B. Lin, H. Lee, E. C. Yi, R. Ossola, R. Aebersold, Human Plasma PeptideAtlas. Proteomics 5, 3497-3500 (2005).
57. M. Polanski, N. L. Anderson, A list of candidate cancer biomarkers for targeted proteomics. Biomark. Insights 1, 1-48 (2007).
58. A. Krogh, B. Larsson, G. von Heijne, E. L. Sonnhammer, Predicting transmembrane protein topology with a hidden Markov model: Application to complete genomes. J. Mol. Biol. 305, 567-580 (2001).
59. J. D. Bendtsen, H. Nielsen, G. Von Heijne, S. Brunak, Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 340, 783-795 (2004).
60. J. D. Bendtsen, L. J. Jensen, N. Blom, G. Von Heijne, S. Brunak, Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng. Des. Sel. 17, 349-356 (2004).
61. Z. Sidak, Rectangular confidence regions for the means of multivariate normal distributions. J. Am. Stat. Assoc. 62, 626-633 (1967).
62. E. L. Lehmann, Nonparametrics Statistical Methods Based on Ranks (Springer, New York, 2006).
63. P. V. Rao, Statistical Research Methods in the Life Sciences (Duxbury Press, New York, 1998).
64. N. D. Mercaldo, K. F. Lau, X. H. Zhou, Confidence intervals for predictive values with an emphasis to case-control studies. Stat. Med. 26, 2170-2183 (2007).
65. L. Reiter, O. Rinner, P. Picotti, R. Hüttenhain, M. Beck, M. Y. Brusniak, M. O. Hengartner, R. Aebersold, mProphet: Automated data processing and statistical validation for large-scale SRM experiments. Nat. Methods 8, 430-435 (2011).
66. P. Kearney, H. Butler, K. Eng, P. Hugo, Protein identification and peptide expression resolver: Harmonizing protein identification with protein expression data. J. Proteome Res. 7, 234-244 (2008).
67. J. D. Storey, R. Tibshirani, Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U.S.A. 100, 9440-9445 (2003).
68. M. S. Pepe, The Statistical Evaluation of Medical Tests for Classification and Prediction (Oxford Univ. Press, New York, 2003), p. 220.
69. T. Farrah, E. W. Deutsch, G. S. Omenn, D. S. Campbell, Z. Sun, J. A. Bletz, P. Mallick, J. E. Katz, J. Malmström, R. Ossola, J. D. Watts, B. Lin, H. Zhang, R. L. Moritz, R. Aebersold, A highconfidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol. Cell. Proteomics 10, M110.006353 (2011).
70. X. Chen, P. Ender, M. Mitchell, C. Wells, Lesson 3 Logistic Regression Diagnostics (UCLA: Statistical Consulting Group); http://www.ats.ucla.edu/stat/ stata/webbooks/logistic/chapter3/statalog3.htm [accessed 6 June 2013].
71. B. S. Holland, M. D. Copenhaver, An improved sequentially rejective Bonferroni test procedure. Biometrics 43, 737 (1987).